Shandong Weigao Group Medical Polymer Future Growth
Future criteria checks 1/6
Shandong Weigao Group Medical Polymer is forecast to grow earnings and revenue by 10.1% and 7.1% per annum respectively. EPS is expected to grow by 10% per annum. Return on equity is forecast to be 9.2% in 3 years.
Key information
10.1%
Earnings growth rate
10.0%
EPS growth rate
| Medical Equipment earnings growth | 41.3% |
| Revenue growth rate | 7.1% |
| Future return on equity | 9.2% |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report
Sep 24
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Recent updates
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
Nov 26Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital
Nov 04Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report
Sep 24Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk
Jun 25Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return
Jun 23Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope
May 22Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15,585 | 2,501 | 2,201 | 3,576 | 6 |
| 12/31/2025 | 14,731 | 2,319 | 1,962 | 3,013 | 7 |
| 12/31/2024 | 13,819 | 2,135 | 2,086 | 2,716 | 7 |
| 6/30/2024 | 12,967 | 1,912 | 2,018 | 2,704 | N/A |
| 3/31/2024 | 13,098 | 1,957 | 2,066 | 2,751 | N/A |
| 12/31/2023 | 13,229 | 2,002 | 2,113 | 2,799 | N/A |
| 9/30/2023 | 13,398 | 2,221 | 1,639 | 2,539 | N/A |
| 6/30/2023 | 13,566 | 2,440 | 1,166 | 2,280 | N/A |
| 3/31/2023 | 13,657 | 2,602 | 1,173 | 2,287 | N/A |
| 12/31/2022 | 13,747 | 2,764 | 1,181 | 2,295 | N/A |
| 9/30/2022 | 13,903 | 2,676 | 1,433 | 2,573 | N/A |
| 6/30/2022 | 14,058 | 2,589 | 1,685 | 2,852 | N/A |
| 3/31/2022 | 13,633 | 2,432 | 1,803 | 2,969 | N/A |
| 12/31/2021 | 13,209 | 2,276 | 1,920 | 3,087 | N/A |
| 9/30/2021 | 12,923 | 2,288 | 2,021 | 3,088 | N/A |
| 6/30/2021 | 12,636 | 2,300 | 2,121 | 3,089 | N/A |
| 3/31/2021 | 12,129 | 2,194 | 1,971 | 2,938 | N/A |
| 12/31/2020 | 11,622 | 2,087 | 1,821 | 2,788 | N/A |
| 9/30/2020 | 11,139 | 1,998 | 1,557 | 2,533 | N/A |
| 6/30/2020 | 10,656 | 1,909 | 1,292 | 2,277 | N/A |
| 3/31/2020 | 10,520 | 1,879 | 1,315 | 2,300 | N/A |
| 12/31/2019 | 10,384 | 1,850 | 1,337 | 2,322 | N/A |
| 9/30/2019 | 9,993 | 1,805 | 1,456 | 2,347 | N/A |
| 6/30/2019 | 9,602 | 1,760 | 1,575 | 2,371 | N/A |
| 3/31/2019 | 9,205 | 1,616 | 1,500 | 2,295 | N/A |
| 12/31/2018 | 8,809 | 1,473 | 1,424 | 2,219 | N/A |
| 6/30/2018 | 7,465 | 1,255 | 383 | 1,812 | N/A |
| 3/31/2018 | 6,879 | 1,255 | N/A | 1,539 | N/A |
| 12/31/2017 | 6,293 | 1,255 | N/A | 1,266 | N/A |
| 6/30/2017 | 5,402 | 1,297 | N/A | 1,233 | N/A |
| 3/31/2017 | 5,511 | 1,165 | N/A | 1,143 | N/A |
| 12/31/2016 | 5,620 | 1,033 | N/A | 1,053 | N/A |
| 9/30/2016 | 6,484 | 1,010 | N/A | 1,042 | N/A |
| 6/30/2016 | 6,237 | 914 | N/A | 1,030 | N/A |
| 3/31/2016 | 6,078 | 1,013 | N/A | 1,041 | N/A |
| 12/31/2015 | 5,919 | 1,113 | N/A | 1,053 | N/A |
| 9/30/2015 | 5,878 | 1,237 | N/A | N/A | N/A |
| 6/30/2015 | 5,610 | 1,196 | N/A | 622 | N/A |
| 3/31/2015 | 5,548 | 1,161 | N/A | N/A | N/A |
| 12/31/2014 | 5,278 | 1,085 | N/A | 711 | N/A |
| 9/30/2014 | 5,011 | 307 | N/A | N/A | N/A |
| 6/30/2014 | 4,996 | 431 | N/A | 794 | N/A |
| 3/31/2014 | 4,769 | 376 | N/A | N/A | N/A |
| 12/31/2013 | 4,613 | 388 | N/A | 720 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1066's forecast earnings growth (10.1% per year) is above the savings rate (2.3%).
Earnings vs Market: 1066's earnings (10.1% per year) are forecast to grow slower than the Hong Kong market (11.6% per year).
High Growth Earnings: 1066's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1066's revenue (7.1% per year) is forecast to grow slower than the Hong Kong market (7.8% per year).
High Growth Revenue: 1066's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1066's Return on Equity is forecast to be low in 3 years time (9.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 17:40 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Weigao Group Medical Polymer Company Limited is covered by 36 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Mann | Barclays |
| Derrick Sun | BNP Paribas Securities (Asia) |
| Feng Qiang Sun | BOCOM International Securities Limited |